Real-world effectiveness of early nirmatrelvir/ritonavir initiation after COVID-19 diagnosis in outpatient setting against severe illness, hospitalization, death, and long COVID in N3C
BMC Infectious Diseases·
- DOI
- 10.1186/s12879-026-13588-w
- PMID
- —
- PMCID
- —
- OpenAlex
- W7203779271
- Study type
- Cohort study
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings suggest nirmatrelvir/ritonavir may reduce risks of both acute severe outcomes and post-acute sequelae including long-COVID in high-risk outpatient populations, supporting continued use as a therapeutic option.
Structured evidence summary
Research question
The study evaluated real-world effectiveness of nirmatrelvir/ritonavir in preventing severe illness, hospitalization, death, and long-COVID among outpatients with COVID-19 who had at least one risk factor for severe disease.
Study design
Population-based retrospective cohort study using emulated target trials within the National COVID Cohort Collaborative, comparing nirmatrelvir/ritonavir initiators to non-initiators across sequential trials beginning on each of the first five days following COVID-19 diagnosis.
Population and setting
Nationwide cohort of outpatients with confirmed SARS-CoV-2 infection diagnosed between December 2021 and February 2023 in the United States, restricted to individuals with at least one risk factor for severe COVID-19 and without contraindicating conditions, medications, or immediate hospitalization at eligibility.
Main findings
Across 921,034 eligible person-trials, nirmatrelvir/ritonavir initiators demonstrated significantly lower hazards compared to non-initiators for all outcomes: severe illness (HR 0.76), hospitalization or death (HR 0.50), hospitalization alone (sdHR 0.52), death (HR 0.33), and long-COVID (sdHR 0.85). Larger associations were observed with earlier treatment initiation and among unvaccinated patients.
Public-health relevance
Findings suggest nirmatrelvir/ritonavir may reduce risks of both acute severe outcomes and post-acute sequelae including long-COVID in high-risk outpatient populations, supporting continued use as a therapeutic option.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. The abstract does not explicitly state limitations; the original paper would be required for complete assessment of potential confounding, generalizability, and other methodological considerations relevant to decision-grade interpretation.
GIDS interpretation
This single retrospective cohort study provides real-world evidence regarding nirmatrelvir/ritonavir effectiveness in a large U.S. outpatient population. The emulated target trial design and sensitivity analyses strengthen causal inference, though residual confounding cannot be fully excluded. Findings are contextual to the study period and population characteristics and should not be extrapolated beyond the available evidence.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 7 auditable classifier relationships to diseases, places, topics, and study design.